Formulations of ZYPREXA® (olanzapine)
ZYPREXA is available in 3 formulations:
- ZYPREXA Tablets are available in these strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg. ZYPREXA is well tolerated by most people, and can be taken with or without meals. No routine blood-level monitoring is required
 |
 |
 |
||
 |
 |
 |
- ZYPREXA® Zydis® (olanzapine) Orally Disintegrating Tablets are a formulation of ZYPREXA that dissolves in the mouth on contact with saliva. It is available in 5-mg, 10-mg, 15-mg, and 20-mg tablets. Tablets can be taken with or without water. To learn more about ZYPREXA Zydis, click here (Phenylketonurics: ZYPREXA Zydis contains phenylalanine)
 |
 |
||
 |
 |
- ZYPREXA® IntraMuscular (Olanzapine for Injection) is used to treat agitation (overexcited, hostile, or threatening behavior) in people with schizophrenia or bipolar disorder. After short-term treatment with ZYPREXA IntraMuscular, a person may receive a prescription for oral ZYPREXA for schizophrenia or bipolar disorder if clinically indicated
Dosing
Schizophrenia
Usual Dose — Oral olanzapine should be administered on a once-a-day schedule without regard to meals, generally beginning with 5 to 10 mg initially, with a target dose of 10 mg/day within several days. Further dosage adjustments, if indicated, should generally occur at intervals of not less than 1 week, since steady state for olanzapine would not be achieved for approximately 1 week in the typical patient. When dosage adjustments are necessary, dose increments/decrements of 5 mg QD are recommended.
Bipolar Disorder
Usual Monotherapy Dose — Oral olanzapine should be administered on a once-a-day schedule without regard to meals, generally beginning with 10 or 15 mg. Dosage adjustments, if indicated, should generally occur at intervals of not less than 24 hours, reflecting the procedures in the placebo-controlled trials. When dosage adjustments are necessary, dose increments/decrements of 5 mg QD are recommended.
Dosing in Special Populations — The recommended starting dose is 5 mg in patients who are debilitated, who have a predisposition to hypotensive reactions, who otherwise exhibit a combination of factors that may result in slower metabolism of olanzapine (eg, nonsmoking female patients ≥65 years of age), or who may be more pharmacodynamically sensitive to olanzapine. When indicated, dose escalation should be performed with caution in these patients.
